Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Research Council grant · Running

PhagoSynCell Design and Chemical Construction of Quasi-living Phagocytic Synthetic Cells for Artificial Phagocytosis of Bacteria

Coordinator
Fundacio Institut De Bioenginyeria De Catalunya, Spain
Runs
1 April 2025 to 31 March 2030
Status
Running
EU funding
€2.0m
Total cost
€2.0m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101170207

What the project is doing

In the project's own words, from its summary on CORDIS.

The growing occurrence of antimicrobial-resistant infections, compounded with the stalling development and approval of new antibiotic drugs, has created a therapeutic gap, threatening a global health crisis. Resistance emerges when bacteria mutate their molecular targets for antibiotics, evading their action. Is it conceivable to design synthetic cells assembled from abiotic synthetic macromolecules, capable of mimicking the most salient features of phagocytosis —Nature’s most selective, effective, and advanced strategy to eradicate pathogens?

The aim of PhagoSynCell is to create Phagocytic Synthetic Cells (PSCs) that selectively recognize, capture, engulf and kill antibiotic-resistant bacteria without generating selection pressure for resistance. Firstly, we will develop the membrane of the PSCs by the simulation-aided synthesis of novel macromolecular amphiphiles (Janus dendrimers and amphiphilic comb polymers) self-assembled into vesicle libraries with functional diversity and phenotype programmability.

We will then study novel methods to facilitate engulfment of micro-objects by leveraging principles of mechanical actuation programmed at the molecular level. We will introduce superselectivity to artificial membranes to selectively capture bacteria. Furthermore, we will develop an antimicrobial strategy triggered and activated by engulfment that disrupts the bacterial membrane —an element highly unsusceptible to evolution.

Finally, we will demonstrate the efficacy of PSCs against pathogenic antibiotic-resistant strains and show their biosafety in cells, organoids, and advanced tissue models as proof-of-concept for future applications. PhagoSynCell will unveil the underlying principles of Artificial Phagocytosis, delivering synthetic cells able to selectively recognize and kill bacteria. Ultimately, this will provide the steppingstone towards the use of synthetic cells as a quasi-living therapeutic —a field I envision will revolutionize medicine.

Topics

Who is involved

OrganisationCityCountryRole
Fundacio Institut De Bioenginyeria De CatalunyaBarcelonaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI